S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The 3-Stock Retirement Blueprint (Ad)
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The 3-Stock Retirement Blueprint (Ad)
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The 3-Stock Retirement Blueprint (Ad)
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
MUST WATCH: Unusual 3-second financial maneuver (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
The 3-Stock Retirement Blueprint (Ad)
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
MUST WATCH: Unusual 3-second financial maneuver (Ad)
Saudi Aramco's profits already $88B as oil prices stay high
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
MUST WATCH: Unusual 3-second financial maneuver (Ad)
OTCMKTS:BRTX

BioRestorative Therapies - BRTX Stock Forecast, Price & News

$3.00
+0.03 (+1.01%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.98
$3.07
50-Day Range
$2.93
$4.77
52-Week Range
$2.75
$26.80
Volume
10,148 shs
Average Volume
14,973 shs
Market Capitalization
$10.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$37.00
BRTX stock logo

About BioRestorative Therapies (OTCMKTS:BRTX) Stock

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Stock News Headlines

Pre-market Movers: BRTX, RCAT, AVCT, ACST, DBVT…
See More Headlines
Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Company Calendar

Today
8/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Miscellaneous health & allied services, not elsewhere classified
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:BRTX
Fax
N/A
Employees
5
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$37.00
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+1,133.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-44,300,000.00
Net Margins
-76,059.10%
Pretax Margin
-76,059.10%

Debt

Sales & Book Value

Annual Sales
$50,000.00
Book Value
$6.18 per share

Miscellaneous

Free Float
2,643,000
Market Cap
$10.95 million
Optionable
Not Optionable
Beta
70.98














BRTX Stock - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings
or view top-rated stocks.

What is BioRestorative Therapies' stock price forecast for 2022?

1 equities research analysts have issued 12 month price objectives for BioRestorative Therapies' stock. Their BRTX share price forecasts range from $37.00 to $37.00. On average, they anticipate the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 1,133.3% from the stock's current price.
View analysts price targets for BRTX
or view top-rated stocks among Wall Street analysts.

How have BRTX shares performed in 2022?

BioRestorative Therapies' stock was trading at $4.34 at the beginning of 2022. Since then, BRTX shares have decreased by 30.9% and is now trading at $3.00.
View the best growth stocks for 2022 here
.

When did BioRestorative Therapies' stock split?

Shares of BioRestorative Therapies reverse split before market open on Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.

What other stocks do shareholders of BioRestorative Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), PharmaCyte Biotech (PMCB), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).

What is BioRestorative Therapies' stock symbol?

BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."

How do I buy shares of BioRestorative Therapies?

Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioRestorative Therapies' stock price today?

One share of BRTX stock can currently be purchased for approximately $3.00.

How much money does BioRestorative Therapies make?

BioRestorative Therapies (OTCMKTS:BRTX) has a market capitalization of $10.95 million and generates $50,000.00 in revenue each year.

How can I contact BioRestorative Therapies?

BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The official website for the company is www.biorestorative.com. The company can be reached via phone at (631) 760-8100 or via email at ir@biorestorative.com.

This page (OTCMKTS:BRTX) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.